Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsLiabilities and Shareholders EquityNon-Current AssetsOther Accumulated ExpensesOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsReceivables - AccuredRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Spyre Therapeutics (SYRE) Receivables (2016 - 2024)

Spyre Therapeutics' Receivables history spans 5 years, with the latest figure at $5.9 million for Q4 2024.

  • For Q4 2024, Receivables changed N/A year-over-year to $5.9 million; the TTM value through Dec 2024 reached $5.9 million, changed N/A, while the annual FY2024 figure was $5.9 million, N/A changed from the prior year.
  • Receivables reached $5.9 million in Q4 2024 per SYRE's latest filing, roughly flat from $5.9 million in the prior quarter.
  • In the past five years, Receivables ranged from a high of $21.5 million in Q1 2021 to a low of $5.9 million in Q2 2024.